<DOC>
	<DOCNO>NCT00311844</DOCNO>
	<brief_summary>This study double-blind , placebo-controlled , cross-over , single-center study desloratadine 5 mg placebo subject 18 year age old history seasonal allergic rhinoconjunctivitis . This study perform examine effect desloratadine compare placebo , sign symptoms allergic conjunctivitis induce direct conjunctival challenge previously identify sensitize antigen , eye subject know sensitive antigen .</brief_summary>
	<brief_title>A Study Effects Desloratadine Conjunctival Allergen Challenge-induced Ocular Signs Symptoms ( Study P04209 )</brief_title>
	<detailed_description />
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<criteria>Willing participate study comply procedure , include adherence dose visit schedule sign informed consent 18 year age old , either sex , race , normal health asymptomatic At least 2year history ( selfreported acceptable ) recurrent seasonal allergic conjunctivitis associate seasonal allergic rhinitis Skin test positive ( skin prick test wheal diameter least 3 mm large diluent control intradermal test wheal diameter least 7 mm large diluent control ) Screening , within 12 month prior Screening Visit , appropriate seasonal allergen , include one following : Kentucky bluegrass ( Poa pratensis ) grass : meadow fescue , rye , Bermuda grass tree : oak , maple , birch cat hair dander ( Felis domesticus ) ragweed Female subject childbearing potential must use acceptable method birth control ( ie , hormonal contraceptive , medically prescribe IUD , condom combination spermicide ) surgically sterilize Female subject childbearing potential must negative urine pregnancy test Screening Visit A calculate bestcorrected visual acuity 0.6 logMar good eye measure ETDRS chart Free clinically significant disease ( SAR ) would interfere study evaluation . Must agree record symptom severity score , medication time , concomitant medication , adverse event accurately consistently daily diary . At Screening Visit , prior qualify conjunctival allergen challenge , subject must ocular symptom severity redness score mild ( &lt; =1 ) prior exposure allergen . Following allergen challenge , subject must achieve ocular itch redness score least moderate ( &gt; =2 ) eye within 10 minute last allergen challenge . For redness , score must &gt; =2 2 3 vessel bed . ( detail section 8.2.6 8.3.2 protocol ) At confirmation visit , subject must ocular itching score eye &gt; =2 2 3 timepoints ( 3 , 5 , 7 minute postchallenge ) . The subject must also follow redness score bilaterally 15 minute postchallenge : &gt; =2 least 2 vessel bed &gt; =6 composite oculare redness score A female pregnant , intend become pregnant study nursing Subject observe designate washout period prohibit medication per protocol Section 7.2 . Antihistamines , inhale nasal cromones , inhale nasal corticosteroid prohibit month prior Screening Visit Current evidence clinically significant hematopoietic , cardiovascular , hepatic , immunologic , renal , neurologic , psychiatric , autoimmune disease disease include would interfere absorption , distribution , metabolism , excretion study drug , subject 's ability complete diary card Clinically significant deviation normal physical ocular exam , may interfere study evaluation affect subject safety Participation another clinical study Use investigational product within 30 day enrollment Subject part study staff family member staff directly involve study History asthma treat inhaled oral corticosteroid , beta2agonists , cromones , theophylline , leukotriene inhibitor complete washout study period without medication A respiratory ocular infection 4 week prior predose evaluation History intranasal drug abuse Known potential hypersensitivity , allergy idiosyncratic reaction study drug excipients , Claritin Upper respiratory tract sinus infection require antibiotic within 28 day Screening , viral upper respiratory infection within 7 day Screening , persistent symptom Screening Visit Dependence nasal , oral , ocular decongestant , nasal topical antihistamine nasal steroid Subjects immunotherapy must remain stable dose study . Subjects receive desensitization treatment within 24 hour prior visit History noncompliance medication treatment protocols History difficulty swallow pill know upper gastrointestinal narrowing abnormal esophageal peristalsis Subject nightshift worker standard asleep night/awake day cycle Unwilling discontinue use contact lenses course study Subject 's ability provide inform consent compromise</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>